Physician profile
Chea Lu
NPI 1194216457
$2,983.15
in general payments reported to CMS, 2019-2025
17 companies · $1,006 in 2025
The $1,006 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.70 · 2022: $110 · 2023: $624 · 2024: $1,225 · 2025: $1,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,855.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $478.51 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $463.37 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $393.82 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $358.23 | 2022-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $234.24 | 2022-2025 | |
| Abbvie INC. | $187.12 | 2022-2025 | |
| Astellas Pharma US INC | $148.35 | 2023-2025 | Veozah |
| Glaxosmithkline, LLC. | $136.38 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.84 | 2023-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $97.80 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $95.67 | 2024-2025 | |
| Exact Sciences Corporation | $93.81 | 2023-2024 | Cologuard Collection Kit |
| Boston Scientific Corporation | $63.82 | 2023-2024 | Watchman, Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.22 | 2023-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $38.73 | 2025 | Rexulti |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $29.80 | 2025 | Zoryve |
| Shield Therapeutics INC | $20.44 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chea Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.